Fungus Infected Woman Who Died After Gene Therapy
By Rick Weiss,
Washington Post
| 08. 20. 2007
The 36-year-old Illinois woman who died last month after being treated with an experimental gene therapy was infected with a fungus that usually causes only a mild illness. But the infection spun out of control and ravaged her organs, suggesting that her immune system was seriously impaired, said a doctor who is part of the medical investigation.
The woman's body was also teeming with a cold-sore virus that the body normally keeps in check, another indication of a faltering immune system. And because of a tear inside her abdomen -- perhaps caused by infection, perhaps by injury -- she had an internal blood clot the size of a watermelon.
No formal cause of death has been declared for Jolee Mohr, who died July 24. Mohr had been generally healthy until July 2, when trillions of genetically engineered viruses were injected into her right knee in an experimental treatment for her rheumatoid arthritis.
The injected viruses were genetically modified so they would suppress the immune system -- which is responsible for the inflammation of rheumatoid arthritis -- only in her...
Related Articles
By Alondra Nelson, Science | 01.15.2026
One of the most interventionist approaches to technology governance in the United States in a generation has cloaked itself in the language of deregulation. In early December 2025, President Donald Trump took to Truth Social to announce a forthcoming “One...
By Daphne O. Martschenko and Julia E. H. Brown, Hastings Bioethics Forum | 01.14.2026
There is growing concern that falling fertility rates will lead to economic and demographic catastrophe. The social and political movement known as pronatalism looks to combat depopulation by encouraging people to have as many children as possible. But not just...
By Danny Finley, Bill of Health | 01.08.2026
The United States Food and Drug Administration (FDA) has a unique funding structure among federal scientific and health agencies. The industries it regulates fund nearly half of its budget. The agency charges companies a user fee for each application
...
By George Janes, BioNews | 01.12.2026
A heart attack patient has become the first person to be treated in a clinical trial of an experimental gene therapy, which aims to strengthen blood vessels after coronary bypass surgery.
Coronary artery bypass surgery is performed to treat...